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Abstract: In our previous studies, we found that behavioral sensitization 
evoked by repeated administration of methamphetamine (METH) was 
suppressed by the activation of the histaminergic neuron system in the brain.  In 
continuation of these studies, we measured the levels of H1 and H2 receptor 
mRNAs in the rat striatum by semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR).  Seven days after the 21 consecutive 
administrations of METH (4 mg/kg, i.p.), the levels of both H1 and H2 receptor 
mRNAs in the rat striatum increased significantly.  But 1 day and 14 days after 
the last administration, there were no significant changes in levels of either H1 
or H2 receptor mRNA in the rat striatum.  These transient increases of H1 and 
H2 receptor mRNA may have some relation to chronic METH abuse and its 
withdrawal.   
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     A biogenic amine, histamine (HA), is widely distributed in the mammalian 
brain and has recently been suggested to be a neurotransmitter or 
neuromodulator[10, 11, 20].  Cell bodies of HA neurons are localized in the 
tuberomammillary nucleus in the posterior hypothalamic region, while their 
varicose fibers are found in almost all regions of the brain.  The HA neuron 
system has been shown to be involved in diverse brain functions and behaviors 
through H1, H2, and H3 receptors, such as arousal, sleep-wake cycle, appetite 
control, seizure, learning and memory, aggressive behaviors, emotion, and so 
on[10, 11, 13, 20].   
     It is well known that methamphetamine (METH) facilitates the release of 
dopamine via especially acting on a dopamine transporter, and induces 
increases of locomotor activity and stereotyped behavior[14, 15].  Repeated 
administration of METH causes a progressive and lasting augmentation of 
locomotion and stereotyped behavior called behavioral sensitization[14, 15].   
     With respect to relationship between METH and the HA neuron system, 
there were several reports that HA agonists inhibited METH-induced locomotor 
hyperactivity and stereotyped behavior in rodents, whereas HA antagonists 
potentiated METH-induced reinforcing effects and stereotyped behavior[5, 6].  
Both H1 and H2 antagonists can potently increase DA levels in the neostriatum 
and nucleus accumbens of rats [1, 17].  In addition, acute administration of 
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METH increases the release of HA in the rat striatum via dopamine D2 
receptors [4].  Recently, our behavioral pharmacological study suggested that 
the HA neuron system had an inhibitory effect on the development of METH-
induced behavioral sensitization through H1 and H2 receptors[5]. Moreover, 
after the METH-induced behavioral sensitization is formed, the release of HA 
and the HDC activity increases in the rat striatum [3, 4].  However there is no 
neurochemical report on changes of H1 and H2 receptors after the development 
of METH-induced behavioral sensitization is accomplished.  In this study, we 
measured changes of H1 and H2 receptor mRNA levels in rat striatum after 
chronic administrations of METH by the semi-quantitative RT-PCR, because 
the striatum has close relationship with METH-induced stereotyped behavior 
and acute and chronic administrations of METH increase HA release in the rat 
striatum [4].  Male Wistar rats weighing 220-240g at the beginning of 
experiments were group-housed (four rats per cage) with free access to food 
and water in a room maintained at 22±2℃ and 65±5% humidity under a 12-h 
light/12-h dark cycle (lights on at 6:00 a.m.).   
     In treatment of METH, rats were injected intraperitoneally (i.p.) with saline 
[0.9% (wt/vol) NaCl] (1 ml/kg) or METH (4 mg/kg) once daily for 21 
consecutive days.  METH (Dainippon, Japan) was dissolved in saline. 
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     Rats were decapitated 1, 7 and 14 days after the last intraperitoneal injection 
of saline or METH.  Total RNAs was prepared from the striatums using acid 
guanidium phenol chloroform extraction (ISOGEN, Wako, Japan).  Total 
RNAs were treated by DNaseI to exclude contamination of genomic DNA as 
follows.  Fifty to 100 μg of total RNA were digested using 120-160 units 
DNaseI (Takara, Japan) in a solution containing 100 mM MgCl2, 10 mM 
dithiothreitol, 25-100 units ribonuclease inhibitor (Wako, Japan) in a total 
volume of 200 μl at 37 ℃ for 60 min. Then, we confirmed that there is no 
genomic DNA contamination by performing PCR with total RNAs as templates 
and H1, H2 and GAPDH primers at 40 cycles. 
    First strand complementary DNA (cDNA) mixture was made by random 
priming from RNA samples containing 4 μg total RNA by using Superscript II 
system (GIBCO BRL, Bethesda) and the procedures recommended by the 
manufacturer.  All PCR reactions were carried out in a total volume of 30 μl of 
solution containing 10 μl of cDNA mixture, 0.75 unit of AmpliTaq Gold 
polymerase (Perkin Elmer, New Jersey), 0.2 mM dNTP mixture, and 1 μM 
specific sets of  H1, H2 and GAPDH primers[2, 12, 18] (H1 receptor: sense 
primer, 5’CTGGTGGTGGTTCTCAGTAGTATC, positions 88-111; antisense 
primer, 5’-CAGCATAAGCAAAGTGGGGAGGTA-3’, positions 598-621; H2 
receptor: sense primer, 5’-AATGGCACAGTTCATTCCTGCT-3’, positions 
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10-31; antisense primer, 5’-ATCCGTTTGGCCTGCTCCCTGGCAA-3’, 
positions 620-644; GAPDH: sense primer, 5’-
ACTGTGGATGGCCCCTCTGGAAA, positions 583-605; antisense primer 5’-
AGGTTTCTCCAGGCGGCATGTCA-3’, positions 758-780).  Cycling 
conditions are 9 min of pre-PCR incubation at 95 ℃, 1 min of denaturation at 
94 ℃, 1 min of annealing at 60 ℃ (H1 and GAPDH) or 65 ℃ (H2), and 1 min of 
extension at 72 ℃ for 17-40 cycles at 2-cycle intervals.  Then products were 
electrophoresed on a 2 % agarose gel containing ethidium bromide.  
Quantitations of PCR products were carried out as described by Nakayama et 
al.[9]. The intensity of the ethidium bromide luminescence was recorded using 
CCD image sensor FOTODYNE FOTO/Analyst Archiver Eclipse system 
(FOTODYNE, Wisconsin) and analyzed by computer software 1-D Basic 
(Advanced American Biotechnology, California).  Reaction cycle-PCR product 
yield curves of each reaction were plotted on semilogarithmic graphs. From the 
graphs, we decided the numbers of cycles that each clone could exponentially 
be amplified.  As an internal control, we also measured the rat GAPDH mRNA 
in the same manner.  Data were analyzed by one way ANOVA, followed by 
Duncan’s test.  In all cases, p values less than 0.05 were considered statistically 
significant. 
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     When PCR with H1 primers were performed for 17-40 cycles at 2-cycle 
intervals, the amount of products increased exponentially with each cycle until 
cycle 33.  To compare the levels of H1 mRNA, we performed PCR at cycle 30-
32.  As shown in Figs. 1 and 2, 7 days after the last administration of 21 
consecutive administrations, the level of H1 receptor mRNA in the rat striatum 
increased significantly.  On the other hand, 1 day and 14 days after the last 
administration, there were no significant changes of H1 mRNA level in the rat 
striatum, being lower than that 7 days after the last administration.  
     When PCR with H2 primers were performed for 17-40 cycles at 2-cycle 
intervals, the amount of products increased exponentially with each cycle until 
cycle 31.  To compare the levels of H2 mRNA quantitatively, we performed 
PCR at cycle 28-30.  As similarly as H1 receptors, Fig. 1 and 3 show that the 
mRNA level of H2 receptor in the rat striatum increased significantly 7 days 
after the last administration, whereas there were no significant changes of H2 
receptor mRNA level in the rat striatum 1 day and 14 days after the last 
administration. 
     The H1 receptor is moderately expressed in the striatum [8].  On the other 
hand, the H2 receptor mRNA is abundant in the basal ganglia [19].  
Nevertheless, the amount of total RNA isolated from the rat striatum is 
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relatively small, semi-quantitative RT-PCR was more useful for detecting the 
H1 and H2 mRNA than Northern blot[9].   
     In this study, we measured the mRNA levels of histamine receptors 1, 7, and 
14 days after the last administration, because the HA content increased 
immediately after the chronic administrations of METH[3], and the release of 
HA increased 7days after the last administration[4], and behavioral 
responsiveness persists for at least several weeks[14].  We found that 7 days 
after the chronic administrations of METH for 21 consecutive days, both H1 
and H2 receptor mRNA levels increased significantly, but one day and 14 days 
after the last administration, there were not significant changes in either H1 or 
H2 receptor mRNA level.  Thus, these increases at the day 7 were transient, and 
the levels of H1 and H2 receptor mRNAs returned to almost the same levels as 
those of control group by the 14 days after the last administration of METH.  
Chronic administration of METH increased HA levels, HA release and HDC 
activity in the rat striatum [3, 4].  Because these consecutive increases of HA 
release and HDC activity in the rat striatum are abolished by the cessation of 
METH treatment, it seems likely that mRNA levels of H1 and H2 receptors are 
subjected to the up-regulation.  
     We have recently reported that pretreatment with a precursor of HA, L-His, 
inhibited the development of METH-induced behavioral sensitization, whereas 
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pretreatment with an inhibitor of HA synthesis, α-fluoromethylhistidine, an H1 
antagonist pyrilamine or an H2 antagonist zolantidine enhanced it [5].  H1 
antagonists have an addictive effect in combination use with opioids [16].  For 
example, in USA, the H1 antagonist tripelennamine has been used illicitly in 
combination with pentazocine by many heroin addicts known as “T’s and 
blues”[7, 10].  Thus, the HA neuron system has an inhibitory effect on the 
development of psychostimulant abuse through H1 and H2 receptors.  It is well-
known that the behavioral sensitization which remains for long time after the 
drug administration is completed shows the vulnerability for relapse of 
psychostimulant abuse and psychostimulant-induced psychosis. However, 
increases of H1 and H2 receptor mRNA levels during the lasting period of 
METH-induced behavioral sensitization are transient, and are consistent with a 
period of METH withdrawal.  Thus, our results in this study may be related to 
withdrawal state of chronic psychostimulant abuse rather than maintenance of 
behavioral sensitization or psychostimulant abuse itself. 
     In conclusion, our study shows that after the chronic administration of 
METH, levels of H1 and H2 receptor mRNA in the rat striatum are increased 
transiently, and the increase may have some relation to withdrawal state of 
chronic psychostimulant abuse. 
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Fig. 1.  H1 and H2 receptor mRNA expressions in the rat striatum 7days after 
the last administration of saline or METH captured by the CCD image sensor.   
Rats were injected intraperitoneally with saline [0.9% (wt/vol) NaCl (1 ml/kg)] 
as control or METH (4 mg/kg) once daily for 21 consecutive days, and 
decapitated 7 days after the last injection, and measured mRNA level by semi-
quantitative RT-PCR.  The GAPDH gene was used as internal control for 
evaluation of the amount of cDNA synthesized. 
 
Fig. 2.  Effect of chronic administration of METH on mRNA levels of H1 
receptor in the rat striatum.  Rats were injected intraperitoneally with saline 
[0.9% (wt/vol) NaCl (1 ml/kg)] or METH (4 mg/kg) once daily for 21 
consecutive days, and decapitated 1 (n = 7), 7 (n = 6) and 14 (n=8) days after 
the last injection, and measured the H1 receptor mRNA level by semi-
quantitative RT-PCR.  The average value of saline injected group is taken as 
100%.  Results are mean values, and their standard errors are shown as vertical 
bars.  Statistical analysis was performed by means of ANOVA (* p < 0.05). 
 
Fig. 3.  Effect of chronic administration of METH on mRNA levels of H2 
receptor in the rat striatum.  Rats were injected intraperitoneally with saline 
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[0.9% (wt/vol) NaCl (1 ml/kg)] or METH (4 mg/kg) once daily for 21 
consecutive days, and decapitated 1 (n = 7), 7 (n = 6) and 14 (n=8) days after 
the last injection, and measured the H2 receptor mRNA level by semi-
quantitative RT-PCR.  The average value of saline injected group is taken as 
100%.  Results are mean values, and their standard errors are shown as vertical 
bars.  Statistical analysis was performed by means of ANOVA (* p < 0.05). 
 15
1 Dringenberg, H.C., de Souza-Silva, M.A., Schwarting, R.K. and Huston, 
J.P., Increased levels of extracellular dopamine in neostriatum and 
nucleus accumbens after histamine H1 receptor blockade, Naunyn 
Schmiedebergs Arch Pharmacol, 358 (1998) 423-9. 
2 Fujimoto, K., Horio, Y., Sugama, K., Ito, S., Liu, Y.Q. and Fukui, H., 
Genomic cloning of the rat histamine H1 receptor, Biochem Biophys 
Res Commun, 190 (1993) 294-301. 
3 Ito, C., Onodera, K., Sakurai, E., Sato, M. and Watanabe, T., The effect 
of methamphetamine on histamine level and histidine decarboxylase 
activity in the rat brain, Brain Res, 734 (1996) 98-102. 
4 Ito, C., Onodera, K., Sakurai, E., Sato, M. and Watanabe, T., Effects of 
dopamine antagonists on neuronal histamine release in the striatum of 
rats subjected to acute and chronic treatments with methamphetamine, J 
Pharmacol Exp Ther, 279 (1996) 271-6. 
5 Ito, C., Onodera, K., Watanabe, T. and Sato, M., Effects of histamine 
agents on methamphetamine-induced stereotyped behavior and 
behavioral sensitization in rats, Psychopharmacology (Berl), 130 (1997) 
362-7. 
 16
6 Itoh, Y., Nishibori, M., Oishi, R. and Saeki, K., Neuronal histamine 
inhibits methamphetamine-induced locomotor hyperactivity in mice, 
Neurosci Lett, 48 (1984) 305-9. 
7 Lange, W.R. and Jasinski, D.R., The clinical pharmacology of 
pentazocine and tripelennamine (T's and Blues), Adv Alcohol Subst 
Abuse, 5 (1986) 71-83. 
8 Lintunen, M., Sallmen, T., Karlstedt, K., Fukui, H., Eriksson, K.S. and 
Panula, P., Postnatal expression of H1-receptor mRNA in the rat brain: 
correlation to L-histidine decarboxylase expression and local 
upregulation in limbic seizures, Eur J Neurosci, 10 (1998) 2287-301. 
9 Nakayama, H., Yokoi, H. and Fujita, J., Quantification of mRNA by 
non-radioactive RT-PCR and CCD imaging system, Nucleic Acids Res, 
20 (1992) 4939. 
10 Onodera, K., Yamatodani, A., Watanabe, T. and Wada, H., 
Neuropharmacology of the histaminergic neuron system in the brain and 
its relationship with behavioral disorders, Prog Neurobiol, 42 (1994) 
685-702. 
11 Prell, G.D. and Green, J.P., Histamine as a neuroregulator, Annu Rev 
Neurosci, 9 (1986) 209-54. 
 17
12 Ruat, M., Traiffort, E., Arrang, J.M., Leurs, R. and Schwartz, J.C., 
Cloning and tissue expression of a rat histamine H2-receptor gene, 
Biochem Biophys Res Commun, 179 (1991) 1470-8. 
13 Schwartz, J.C., Arrang, J.M., Garbarg, M., Pollard, H. and Ruat, M., 
Histaminergic transmission in the mammalian brain, Physiol Rev, 71 
(1991) 1-51. 
14 Segal, D.S. and Kuczenski, R., Behavioral pharmacology of 
amphetamine. In A.K. Cho and D.S. Segal (Eds.), Amphetamine and its 
analogs, Academic Press, New York, 1994, pp. 115-150. 
15 Seiden, L.S., Sabol, K.E. and Ricaurte, G.A., Amphetamine: effects on 
catecholamine systems and behavior, Annu Rev Pharmacol Toxicol, 33 
(1993) 639-77. 
16 Suzuki, T., Masukawa, Y., Shiozaki, Y. and Misawa, M., Potentiation of 
pentazocine conditioned place preference by tripelennamine in rats, 
Psychopharmacology, 105 (1991) 9-12. 
17 Suzuki, T., Mori, T., Tsuji, M., Misawa, M. and Onodera, K., 
Generalization of D-, L- and DL-chlorpheniramine and zolantidine to 
the discriminative stimulus effects of cocaine and methamphetamine, 
Behav Pharmacol, 8 (1997) 718-24. 
 18
18 Tso, J.Y., Sun, X.H., Kao, T.H., Reece, K.S. and Wu, R., Isolation and 
characterization of rat and human glyceraldehyde-3- phosphate 
dehydrogenase cDNAs: genomic complexity and molecular evolution of 
the gene, Nucleic Acids Res, 13 (1985) 2485-502. 
19 Vizuete, M.L., Traiffort, E., Bouthenet, M.L., Ruat, M., Souil, E., 
Tardivel-Lacombe, J. and Schwartz, J.C., Detailed mapping of the 
histamine H2 receptor and its gene transcripts in guinea-pig brain, 
Neuroscience, 80 (1997) 321-43. 
20 Watanabe, T. and Wada, H., Histaminergic Neurons: Morphology and 
Function., CRC Press, Boca Raton, Florida, 1991. 
